Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: (erice OR price)
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Search alternatives
:
erice »
eric
,
erich
,
erica
Showing
1
-
20
of
210
Search:
'(erice OR price)'
,
query time: 0.12s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Pharmacoeconomic review report: Von Willebrand factor (Recombinant) (Vonvendi) (Shire Pharma Canada ULC, now part of Takeda Canada Inc.) : indication: for the treatment and control...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... co-administration with rFVIII. A
price
reduction of 40% is required for rVWF to have a treatment...
”
Read Now
2
Pharmacoeconomic report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication: treatment of neovascular (wet) age-related macular degeneration (AMD)
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... was 0% at a threshold of $50,000 per QALY (and even at a threshold of $100,000 per QALY).
Price
...
”
Read Now
3
Pharmacoeconomic review report: Riociguat (Adempas)
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
... titration phase. The manufacturer submitted a
price
of $42.75 per tablet for all dosage strengths based...
”
Read Now
4
Pharmacoeconomic report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) : indication: the acute, intermittent treatment of "OFF" episodes in patients wi...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
.... In the CADTH reanalyses, at the submitted
price
, APO SL was less costly when compared with the list
price
...
”
Read Now
5
Pharmacoeconomic review report: Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)
Published 2018
CADTH
“
... and whether cirrhosis is present. At the time of submission, the manufacturer submitted a
price
of $797.62...
”
Read Now
6
Pharmacoeconomic review report: Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)
Published 2018
CADTH
“
... and whether cirrhosis is present. At the time of submission, the manufacturer submitted a
price
of $797.62...
”
Read Now
7
Pharmacoeconomic review report: Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
CADTH
“
... is one drop in the affected eye(s) once daily. The manufacturer-submitted
price
was $20.54 per pack of 30...
”
Read Now
8
Pharmacoeconomic review report: Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
CADTH
“
... is one drop in the affected eye(s) once daily. The manufacturer-submitted
price
was $20.54 per pack of 30...
”
Read Now
9
Pharmacoeconomic review report: Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited) : indication: treatment of adults and pediatric patients one year of age and above w...
Published 2020
CADTH
“
... before initiation of treatment. At the manufacturer's submitted
price
of $904.00 per vial2 and at a...
”
Read Now
10
Pharmacoeconomic review report: Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited) : indication: treatment of adults and pediatric patients one year of age and above w...
Published 2020
CADTH
“
... before initiation of treatment. At the manufacturer's submitted
price
of $904.00 per vial2 and at a...
”
Read Now
11
Pharmacoeconomic review report: Insulin degludec and liraglutide injection (Xultophy) (Novo Nordisk Canada Inc.)
Published 2019
CADTH
“
... to 1.8 mg daily) do not provide adequate glycemic control. The current submitted
price
for IDegLira...
”
Read Now
12
Pharmacoeconomic report: Eculizumab (Soliris) : Alexion Pharma Canada Corporation : indication : adult patients with generalized myasthenia gravis
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... (WTP) threshold of $50,000 per QALY. A
price
reduction of 91% would be required to achieve an ICER...
”
Read Now
13
Pharmacoeconomic review report: Insulin degludec and liraglutide injection (Xultophy) (Novo Nordisk Canada Inc.)
Published 2019
CADTH
“
... to 1.8 mg daily) do not provide adequate glycemic control. The current submitted
price
for IDegLira...
”
Read Now
14
Pharmacoeconomic report: Emicizumab (Hemlibra) : Hoffman-La Roche Ltd. : indication: bleeding prevention, hemophilia A.
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
15
Pharmacoeconomic review report: Glycopyrrolate (Cuvposa) : (Medexus pharmaceuticals, inc.) : indication: chronic severe drooling, neurologic (pediatric)
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...]). It is available in a 1 mg/5 mL concentration in 473 mL bottles at a submitted
price
of $625.00 per bottle...
”
Read Now
16
Pharmacoeconomic report: Indacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler) : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenan...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... the
price
of the inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA)
price
and assuming...
”
Read Now
17
Pharmacoeconomic report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) : indication: multiple sclerosis, relapsing-remitting
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
..., these conclusions were highly uncertain. At minimum, ofatumumab should be
priced
no higher than the lowest-cost DMT...
”
Read Now
18
Pharmacoeconomic report: Esketamine hydrochloride (Spravato) (Janssen inc.) : indication : major depressive disorder in adults
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... per QALY and a 31% likelihood at a $100,000 per QALY threshold.
Price
reductions can improve the cost...
”
Read Now
19
Pharmacoeconomic review report: Sapropterin dihydrochloride (Kuvan)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... within the range of 5 to 20 mg/kg/day according to response to therapy. The confidential
price
per 100 mg...
”
Read Now
20
Pharmacoeconomic report: Satralizumab (Enspryng) : (Hoffmann-La Roche Limited) : indication : neuromyelitis optica spectrum disorder
Published 2021
Canadian Agency for Drugs and Technologies in Health
1
2
3
4
5
6
7
8
9
10
11
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
330 - Economics
145
610 - Medicine & health
89
140 - Specific philosophical schools
22
700 - The arts; fine & decorative arts
13
580 - Plants (Botany)
2
615 - Pharmacology & therapeutics
2
Language
English
210
Collection
National Center for Biotechnology Information
210
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
23
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
2
Chao, Yi-Sheng
2
Grobelna, Aleksandra
2
Klarenbach, Scott
1
more ...
Manns, Braden
1
So, Helen
1
Tonelli, Marcello
1
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%28erice+OR+price%29&type=AllFields
Send by Email
×
Loading...